Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells

Oncotarget

Volumn 6, Issue 31, 2015, Pages 31461-31478

  Kopecka, Joanna ^a   Porto, Stefania ^b   Lusa, Sara ^c   Gazzano, Elena ^a   Salzano, Giuseppina ^d   Giordano, Antonio ^e,f   Desiderio, Vincenzo ^b   Ghigo, Dario ^a   Caraglia, Michele ^b,e   De Rosa, Giuseppe ^c   Riganti, Chiara ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d NORTHEASTERN UNIVERSITY   (United States)

^e Temple University   (United States)

^f UNIVERSITY OF SIENA   (Italy)

Author keywords

ATP binding cassette transporters; Hypoxia inducible factor 1 ; Multidrug resistance; Self assembling nanoparticles; Zoledronic acid

Indexed keywords

ABC TRANSPORTER; GERANYLTRANSFERASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ISOPRENOID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NANOPARTICLE; RAS PROTEIN; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; HIF1A PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CITRIC ACID CYCLE; CONTROLLED STUDY; DRUG FORMULATION; ELECTRON TRANSPORT; ENCAPSULATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SYNTHESIS; FEMALE; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; RESPIRATORY CHAIN; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; LUNG NEOPLASMS; METABOLISM; NUDE MOUSE; OXIDATIVE STRESS; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; BLOTTING, WESTERN; BONE DENSITY CONSERVATION AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DIPHOSPHONATES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMIDAZOLES; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; OXIDATIVE STRESS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84945587798     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5058     Document Type: Article

References (53)

1. Clendening JW, Pandyra A, Boutrosa PC, El Ghamrasni S, Khosravi F, Trentin GA, Martirosyan A, Hakem A, Hakem R, Jurisica I, Penn LZ. Proc Natl Acad Sci USA. 2010; 107:15051-15056.
2. Freed-Pastor WA, Mizuno H, Zhao X, Langerød A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, Bissell MJ, Osborne TF, Tian B, et al. Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway. Cell. 2012; 148:244-258.
3. Thurnher M, Nussbaumer O, Gruenbacher G. Novel Aspects of Mevalonate Pathway Inhibitors as Antitumor Agents. Clin Cancer Res. 2012; 18:3524-3531.
4. Pandyra A, Mullen PJ, Kalkat M, Yu R, Pong JT, Li Z, Trudel S, Lang KS, Minden MD, Schimmer AD, Penn LZ. Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop. Cancer Res. 2014; 74:4772-4782.
5. Karlic H, Thaler R, Gerner C, Grunt T, Proestling K, Haider F, Varga F. Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells. Cancer Genet. 2015; May 208:241-52.
6. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2:48-58.
7. Kopecka J, Campia I, Olivero P, Pescarmona G, Ghigo D, Bosia A, Riganti C. A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells. J Control Release. 2011; 149:196-205.
8. Riganti C, Castella B, Kopecka J, Campia I, Coscia M, Pescarmona G, Bosia A, Ghigo D, Massaia M. Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells. Plos One. 2013; 8:e60975.
9. Sharom FJ. Complex Interplay between the P-Glycoprotein Multidrug Efflux Pump and the Membrane: Its Role in Modulating Protein Function. Front Oncol. 2014; 4:e41.
10. Fenyvesi F, Fenyvesi E, Szente L, Goda K, Bacsó Z, Bácskay I, Váradi J, Kiss T, Molnár E, Janáky T, Szabó G Jr, Vecsernyés M. P-glycoprotein inhibition by membrane cholesterol modulation. Eur J Pharm Sci. 2008; 34:236-242.
11. Schmidmaier R, Baumann P, Simsek M, Dayyani F, Emmerich B, Meinhardt G. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion mediated drug resistance (CAM-DR) in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood. 2004; 104:1825-1832.
12. Riganti C, Orecchia S, Pescarmona G, Betta PG, Ghigo D, Bosia A. Statins revert doxorubicin resistance via nitric oxide in malignant mesothelioma. Int J Cancer. 2006; 119:17-27.
13. Salaroglio IC, Campia I, Kopecka J, Gazzano E, Orecchia S, Ghigo D, Riganti C. Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma. Oncotarget. 2015; 6:1128-1142.
14. Pluchino KM, Hall MD, Goldsborough AS, Callaghan R, Gottesman MM. Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updat. 2012; 15:98-105.
15. Szakács G, Hall MD, Gottesman MM, Boumendjel A, Kachadourian R, Day BJ, Baubichon-Cortay H, Di Pietro A. Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance. Chem Rev. 2014; 114:5753-5774.
16. Callaghan R, Luk F, Bebawy M. Inhibition of the Multidrug Resistance P-glycoprotein; Time for a Change of Strategy? Drug Metab Dispos. 2014; 42:623-631.
17. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ. Structureactivity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001; 296:235-242.
18. O'Donnell JL, Joyce MR, Shannon AM, Harmey J, Geraghty J, Bouchier-Hayes D. Oncological implications of hypoxia inducible factor-1alpha (HIF-1alpha) expression. Cancer Treat Rev. 2006; 32:407-416.
19. Caraglia M, Marra M, Naviglio S, Botti G, Addeo R, Abbruzzese A. Zoledronic acid: an unending tale for an antiresorptive agent. Expert Opin Pharmacother. 2010; 11:141-154.
20. Salzano G, Marra M, Porru M, Zappavigna S, Abbruzzese A, La Rotonda MI, Leonetti C, Caraglia M, De Rosa G. Self-assembly nanoparticles for the delivery of bisphosphonates into tumors. Int J Pharm. 2011; 403:292-297.
21. Marra M, Salzano G, Leonetti C, Tassone P, Scarsella M, Zappavigna S, Calimeri T, Franco R, Liguori G, Cigliana G, Ascani R, La Rotonda MI, Abbruzzese A, et al. Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomedicine. 2011; 7:955-964.
22. Marra M, Salzano G, Leonetti C, Porru M, Franco R, Zappavigna S, Liguori G, Botti G, Chieffi P, Lamberti M, Vitale G, Abbruzzese A, La Rotonda MI, et al. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study. Biotechnol Adv. 2012; 30:302-309.
23. Porru M, Zappavigna S, Salzano G, Luce A, Stoppacciaro A, Balestrieri ML, Artuso S, Lusa S, De Rosa G, Leonetti C, Caraglia M. Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid. Oncotarget. 2014; 5:10446-10459.
24. Schiraldi C, Zappavigna S, D' Agostino A, Porto S, Gaito O, Lusa S, Lamberti M, De Rosa M, De Rosa G, Caraglia M. Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: a comparative analysis through time lapse video-microscopy technique. Cancer Biol Ther. 2014; 15:1524-1532.
25. Sharma V, Dixit D, Koul N, Mehta VS, Sen E. Ras regulates interleukin-1β-induced HIF-1α transcriptional activity in glioblastoma. J Mol Med. 2011; 89:123-136.
26. Yu M, Ocana A, Tannock IF. Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? Cancer Met Rev. 2013; 32:211-227.
27. Martinez-Outschoorn UE, Pestell RG, Howell A, Tykocinski ML, Nagajyothi F, Machado FS, Tanowitz HB, Sotgia F, Lisanti MP. Energy transfer in "parasitic" cancer metabolism: mitochondria are the powerhouse and Achilles' heel of tumor cells. Cell Cycle. 2011; 10:4208-4216.
28. Tavares-Valente D, Baltazar F, Moreira R, Queirós O. Cancer cell bioenergetics and pH regulation influence breast cancer cell resistance to paclitaxel and doxorubicin. J Bioenerg Biomembr. 2013; 45:467-475.
29. Martinez-Outschoorn UE, Lin Z, Ko YH, Goldberg AF, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell A, Sotgia F, Lisanti MP. Understanding the metabolic basis of drug resistance: therapeutic induction of the Warburg effect kills cancer cells. Cell Cycle. 2011; 10:2521-2528.
30. Daubiné F, Le Gall C, Gasser J, Green J, Clézardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst. 2007; 99:322-330.
31. Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, Holen I, Mönkkönen H, Boccadoro M, Forni G, Musiani P, Bosia A, Cavallo F, et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med. 2010; 14:2803-2815.
32. Vitale G, Zappavigna S, Marra M, Dicitore A, Meschini S, Condello M, Arancia G, Castiglioni S, Maroni P, Bendinelli P, Piccoletti R, van Koetsveld PM, Cavagnini F, et al. The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells. Biotechnol Adv. 2012; 30:169-184.
33. Dicitore A, Caraglia M, Colao A, Zappavigna S, Mari D, Hofland LJ, Persani L, Vitale G. Combined treatment with PPAR-γ agonists in pancreatic cancer: a glimmer of hope for cancer therapy? Curr Cancer Drug Targets. 2013; 13:460-471.
34. Dicitore A, Caraglia M, Gaudenzi G, Manfredi G, Amato B, Mari D, Persani L, Arra C, Vitale G. Type I interferonmediated pathway interacts with peroxisome proliferator activated receptor-γ (PPAR-γ): at the cross-road of pancreatic cancer cell proliferation. Biochim Biophys Acta. 2014; 1845:42-52.
35. Campia I, Buondonno I, Castella B, Rolando B, Kopecka J, Gazzano E, Ghigo D, Riganti C. An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells. PLoS One. 2015; 10:e0126159.
36. Di Martino MT, Arbitrio M, Guzzi PH, Leone E, Baudi F, Piro E, Prantera T, Cucinotto I, Calimeri T, Rossi M, Veltri P, Cannataro M, Tagliaferri P, et al. A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling. Br J Haematol. 2011; 154:529-533.
37. Melisi D, Caputo R, Damiano V, Bianco R, Veneziani BM, Bianco AR, De Placido S, Ciardiello F, Tortora G. Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocr Relat Cancer. 2005; 12:1051-1058.
38. Markman JL, Rekechenetskiy A, Holler E, Ljubimova JY. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev. 2013; 65:1866-1879.
39. Kobayashi T, Ishida T, Okada Y, Ise S, Harashima H, Kiwada H. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int J Pharm. 2007; 329:94-102.
40. Kirtane AR, Kalscheuer SM, Panyam J. Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities. Adv Drug Deliv Rev. 2013; 65:1731-1747.
41. Pedrini I, Gazzano E, Chegaev K, Rolando B, Marengo A, Kopecka J, Fruttero R, Ghigo D, Arpicco S, Riganti C. Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells. Mol Pharm. 2014; 11:3068-3079.
42. Minko T, Rodriguez-Rodriguez L, Pozharov V. Nanotechnology approaches for personalized treatment of multidrug resistant cancers. Adv Drug Deliv Rev. 2013; 65:1880-1895.
43. Kopecka J, Salzano G, Campia I, Lusa S, Ghigo D, De Rosa G, Rigani C. Insights in the chemical components of liposomes responsible for P-glycoprotein inhibition. Nanomedicine. 2014; 10:77-87.
44. Riganti C, Voena C, Kopecka J, Corsetto PA, Montorfano G, Enrico E, Costamagna C, Rizzo AM, Ghigo D, Bosia A. Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells. Mol Pharm. 2011; 8:683-700.
45. Peetla C, Vijayaraghavalu S, Labhasetwar V. Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles. Adv Drug Deliv Rev. 2013; 65:1686-1698.
46. Gelsomino G, Corsetto PA, Campia I, Montorfano G, Kopecka J, Castella B, Gazzano E, Ghigo D, Rizzo AM, Riganti C. Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition. Mol Cancer. 2013; 12:e137.
47. Campia I, Sala V, Kopecka J, Leo C, Mitro N, Costamagna C, Caruso D, Pescarmona G, Crepaldi T, Ghigo D, Bosia A, Riganti C. Digoxin and ouabain induce the efflux of cholesterol via LXR signalling and the synthesis of ATP in cardiomyocytes. Biochem J. 2012; 447:301-311.
48. Bergandi L, Silvagno F, Russo I, Riganti C, Anfossi G, Aldieri E, Ghigo D, Trovati M, Bosia A. Insulin stimulates glucose transport via nitric oxide/cyclic GMP pathway in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003; 23:2215-2221.
49. Sharma B. Kinetic Characterisation of Phosphofructokinase Purified from Setariacervi: A Bovine Filarial Parasite. Enzyme Res. 2011; 2011:939472-939482.
50. Beutler E. Red cell metabolism. A manual of biochemical methods. Grune & Stratton Editors New York and London; 1975.
51. Riganti C, Gazzano E, Polimeni M, Costamagna C, Bosia A, Ghigo D. Diphenyleneiodonium inhibits the cell redox metabolism and induces oxidative stress. J Biol Chem. 2004; 279:47726-47731.
52. Campia I, Lussiana C, Pescarmona G, Ghigo D, Bosia A, Riganti C. Geranylgeraniol prevents the cytotoxic effects of mevastatin in THP-1 cells, without decreasing the beneficial effects on cholesterol synthesis. Br J Pharmacol. 2009; 158:1777-1786.
53. Caraglia M, Giuberti G, Marra M, Addeo R, Montella L, Murolo M, Sperlongano P, Vincenzi B, Naviglio S, Prete SD, Abruzzese A, Stiuso P. Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death Dis. 2011; 2:e150.